HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

propan-2-yl 4- (6- (4- (2,5- difluorophenoxy)- 3- hydroxybut- 1- en- 1- yl)- 7- hydroxyoctahydro- 2H- cyclopenta(b)oxepin- 3- yl)butanoate

a prodrug of ONO-AG-367; structure in first source

Also Known As:

ONO-9054; sepetoprost

Networked: 5 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Ethers: 242
  - Cyclic Ethers: 12
    - Oxepins: 16
      - propan-2-yl 4-(6-(4-(2,5-difluorophenoxy)-3-hydroxybut-1-en-1-yl)-7-hydroxyoctahydro-2H-cyclopenta(b)oxepin-3-yl)butanoate: 5
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Oxepins: 16
    - propan-2-yl 4-(6-(4-(2,5-difluorophenoxy)-3-hydroxybut-1-en-1-yl)-7-hydroxyoctahydro-2H-cyclopenta(b)oxepin-3-yl)butanoate: 5

Experts

1.	Ward, Caroline L: 4 articles (01/2017 - 12/2015)
2.	Ouchi, Takafumi: 3 articles (10/2016 - 12/2015)
3.	Wood, Andrew: 3 articles (10/2016 - 12/2015)
4.	Berlin, Michael S: 2 articles (01/2017 - 06/2016)
5.	Harris, Alon: 2 articles (01/2017 - 10/2016)
6.	Jamil, Alam: 2 articles (01/2017 - 12/2015)
7.	Fujii, Akifumi: 2 articles (10/2016 - 06/2016)
8.	Rowe-Rendleman, Cheryl L: 2 articles (10/2016 - 12/2015)
9.	Suto, Fumitaka: 2 articles (12/2015 - 04/2015)
10.	Miller Ellis, Eydie: 1 article (01/2017)

Related Diseases

1.	Ocular Hypertension (Glaucoma, Suspect) 01/01/2017 - "ONO-9054 is being developed for the reduction of intraocular pressure (IOP) in patients with ocular hypertension (OHT) and open-angle glaucoma (OAG). " 10/01/2016 - "To assess pharmacodynamic and safety profiles of ONO-9054 following single and multiple day dosing in subjects with ocular hypertension or open-angle glaucoma. " 06/01/2016 - "EP3/FP dual receptor agonist ONO-9054 administered morning or evening to patients with open-angle glaucoma or ocular hypertension: results of a randomised crossover study." 12/01/2015 - "This supports further evaluation of ONO-9054 for the treatment of ocular hypertension and open angle glaucoma. " 06/01/2016 - "The novel prostaglandin E (EP) 3 and prostaglandin F (FP) receptor agonist ONO-9054 is effective in lowering intraocular pressure (IOP) in patients with ocular hypertension and open-angle glaucoma when administered once daily. "
2.	Open-Angle Glaucoma (Glaucoma, Open Angle) 01/01/2017 - "ONO-9054 is being developed for the reduction of intraocular pressure (IOP) in patients with ocular hypertension (OHT) and open-angle glaucoma (OAG). " 10/01/2016 - "To assess pharmacodynamic and safety profiles of ONO-9054 following single and multiple day dosing in subjects with ocular hypertension or open-angle glaucoma. " 06/01/2016 - "EP3/FP dual receptor agonist ONO-9054 administered morning or evening to patients with open-angle glaucoma or ocular hypertension: results of a randomised crossover study." 12/01/2015 - "This supports further evaluation of ONO-9054 for the treatment of ocular hypertension and open angle glaucoma. " 06/01/2016 - "The novel prostaglandin E (EP) 3 and prostaglandin F (FP) receptor agonist ONO-9054 is effective in lowering intraocular pressure (IOP) in patients with ocular hypertension and open-angle glaucoma when administered once daily. "
3.	Mydriasis 04/01/2015 - "In ophthalmologic and histopathologic evaluations, slight and transient mydriasis was occasionally observed and no histopathologic lesions attributable to ONO-9054 were noted. "

Related Drugs and Biologics

1.	Prostaglandins
2.	prostaglandin F2alpha receptor
3.	prostaglandin E3 (PGE3)

Related Therapies and Procedures

1.	Therapeutics